Eidos therapeutics, inc. (EIDX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash Flows From Operating Activities:
Net loss

-48,926

-37,835

-28,709

-46,254

-43,582

-40,725

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

89

77

69

65

61

56

0

0

0

Stock-based compensation expense

6,336

5,373

4,550

3,649

3,102

2,526

0

0

0

Amortization of debt discount and issuance costs

0

-

-

-

-

-

-

-

-

Accrued interest on Convertible Promissory Notes payable

-

-

-

-

-

48

0

0

0

Change in fair value of derivative liability

0

-

-

-

-

100

0

0

0

Change in fair value of redeemable convertible preferred stock warrant liability

-

-

-

-

-

-2,628

0

0

0

Amortization of debt discount

-

-

-

-

-

963

0

0

0

Loss on disposal of asset

-

-59

0

0

0

-

-

-

-

Changes in assets and liabilities:
Related party receivable

53

51

54

176

-4

-33

0

0

0

Prepaid expenses and other current assets

1,792

2,889

2,155

1,683

1,536

1,305

0

0

0

Other assets

4,070

5,708

6,224

3,383

1,730

752

0

0

0

Accounts payable

760

1,195

1,149

119

1,544

1,390

0

0

0

Accrued expenses and other liabilities

7,064

8,015

6,468

3,201

1,239

1,416

0

0

0

Related party payable

-84

60

166

-187

80

-116

0

0

0

Net cash used in operating activities

-40,417

-31,648

-24,739

-44,635

-37,518

-33,301

0

0

0

Cash Flows From Investing Activities:
Purchases of property and equipment

0

-

-

-

-

150

0

0

0

Net cash used in investing activities

0

-

-

-

-

-150

0

0

0

Cash Flows From Financing Activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

63,875

0

0

0

Proceeds from issuance of Convertible Promissory Notes payable

-

-

-

-

-

10,000

0

0

0

Proceeds from issuance of common stock upon exercise of stock options and restricted stock

0

-

-

-

0

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

0

Proceeds from the issuance of common stock in at-the-market offering

-

-

-

-

-

-

-

0

0

Net cash provided by financing activities

90,146

65,885

24,146

-598

159,349

185,101

0

0

0

Net increase (decrease) in cash and cash equivalents

49,451

34,010

-746

-45,289

121,795

151,650

0

0

0

Other supplemental information
Interest paid

0

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash activities:
Lease liability arising from the right of use asset

-

5,155

0

0

0

-

-

-

-

Vesting of restricted stock and early exercised options

147

149

147

211

190

170

0

0

0

Conversion of Convertible Promissory Notes payable and accrued interest into redeemable convertible preferred stock

-

-

-

-

-

14,354

0

0

0

Open Market Sale Agreement
Proceeds from the issuance of common stock in at-the-market offering

0

-

-

-

-

-

-

-

-